公开(公告)号：US11465969B2

公开(公告)日：2022-10-11

申请号：US17263224

申请日：2019-08-16

Applicant: AMGEN INC. ,  CYTOKINETICS, INC.

Inventor： Henry Morrison ,  Sheng Cui ,  Kyle Quasdorf ,  Evelyn Yanez ,  Bin Peter Quan ,  Ron C. Kelly ,  Sebastien Caille ,  Lingyun Xiao ,  David Pearson ,  Jaclyn Raeburn ,  Ailsa Golightly ,  Bradley Morgan ,  Matthew Peterson ,  Alex Eberlin ,  Alexander Oblezov

IPC: C07D213/75

Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

公开(公告)号：US20210221771A1

公开(公告)日：2021-07-22

申请号：US17263224

申请日：2019-08-16

Applicant: AMGEN INC. ,  CYTOKINETICS, INC.

Inventor： Henry Morrison ,  Sheng Cui ,  Kyle Quasdorf ,  Evelyn Yanez ,  Bin Peter Quan ,  Ron C. Kelly ,  Sebastien Caille ,  Lingyun Xiao ,  David Pearson ,  Jaclyn Raeburn ,  Ailsa Golightly ,  Bradley Morgan ,  Matthew Peterson ,  Alex Eberlin ,  Alexander Oblezov

IPC: C07D213/75

Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

公开(公告)号：US10344041B2

公开(公告)日：2019-07-09

申请号：US15966157

申请日：2018-04-30

Applicant: AMGEN, INC.

Inventor： David Bauer ,  Matthew Bio ,  Melanie Cooke ,  Katrina W. Copeland ,  Matthew Peterson ,  Michele Potashman ,  Roman Shimanovich ,  Helming Tan

IPC: C07D519/00 ,  A61K31/52 ,  C07C55/10 ,  C07C55/12 ,  C07C57/10 ,  C07C57/145 ,  C07C275/02

Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

公开(公告)号：US10053452B2

公开(公告)日：2018-08-21

申请号：US15101373

申请日：2014-11-25

Applicant: AMGEN INC.

Inventor： Mary Chaves ,  Matthew Bio ,  Matthew Peterson

IPC: C07D409/14 ,  A61K31/506 ,  C07C309/04 ,  C07C309/30

CPC classification number: C07D409/14 ,  C07B2200/13 ,  C07C309/04 ,  C07C309/30

Abstract: The present invention relates to crystalline forms and co-crystal forms of pharmaceutically acceptable salts of the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine (AMG 900, and pharmaceutical compositions comprising said crystalline and co-crystal forms thereof. The invention further provides uses of the crystalline forms and compositions, to treat cancer, including various types of solid tumors and hematologic cancer including myeloma and leukemia.

公开(公告)号：US09981988B2

公开(公告)日：2018-05-29

申请号：US15293511

申请日：2016-10-14

Applicant: AMGEN, INC.

Inventor： David Bauer ,  Matthew Bio ,  Melanie Cooke ,  Katrina W. Copeland ,  Matthew Peterson ,  Michele Potashman ,  Roman Shimanovich ,  Helming Tan

IPC: C07D519/00 ,  A61K31/52 ,  C07C55/10 ,  C07C55/12 ,  C07C57/10 ,  C07C57/145 ,  C07C275/02

CPC classification number: C07D519/00 ,  A61K31/52 ,  C07B2200/13 ,  C07C55/10 ,  C07C55/12 ,  C07C57/10 ,  C07C57/145 ,  C07C275/02

Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.